This is the Drug That Could Kick Regeneron's Stock Into Gear Post author:Sam Post published:December 13, 2017 Post category:BioPharma Regeneron shares have made little headway since the disappointing launch of Praluent in 2015. Source: BioSpace You Might Also Like Bay Area's Coherus Craters After the FDA Spurns Its Biosimilar for Amgen's Neulasta June 11, 2017 <b>RPRD Diagnostics</b> Announces Strategic Collaboration With <b>Children's Minnesota</b> To Advance Clinical Pharmacogenomics February 12, 2017 What You Need to Know About BlueRock Therapeutics January 2, 2018
<b>RPRD Diagnostics</b> Announces Strategic Collaboration With <b>Children's Minnesota</b> To Advance Clinical Pharmacogenomics February 12, 2017